Upstream Bio (UPB)

Executive Summary

Upstream Bio is a clinical-stage biotechnology company advancing verekitug, a first-in-class monoclonal antibody targeting the TSLP receptor for inflammatory respiratory diseases. By blocking TSLP, a key upstream cytokine, verekitug aims to disrupt multiple inflammatory pathways, potentially offering superior efficacy and dosing convenience over existing biologics like Tezspire. The company's lead program is in severe asthma (Phase 2, NCT06196879), with top-line data expected in mid-2026. Additional Phase 2 trials are ongoing in COPD and chronic rhinosinusitis with nasal polyps (CRSwNP), the latter having completed enrollment and data readout in mid-2025. Upstream Bio went public in 2024 and is well-capitalized to advance its pipeline through key value-driving milestones. The company's differentiated approach positions it to address significant unmet need in large respiratory markets. Positive Phase 2 results in severe asthma could de-risk the program and support progression to Phase 3, potentially leading to a pivotal data release within 12-18 months. The COPD trial also represents a substantial opportunity, given limited biologic options. With a novel mechanism and a focused strategy, Upstream Bio is a compelling player in the inflammation and immunology space.

Upcoming Catalysts (preview)

• Q3 2026Top-line Phase 2 data for verekitug in severe asthma (NCT06196879)60% success
• Q4 2026Initiation or update of Phase 2 COPD trial (NCT06981078) interim analysis50% success
• TBDPotential partnership or licensing deal for verekitug in ex-US markets40% success